Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05772156 · ClinicalTrials.gov registry record · Phase 4
Prophylactic Methylergonovine for Twin Cesarean
A Phase 4 study of Postpartum Hemorrhage and Twin; Complicating Pregnancy, sponsored by Columbia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT05772156 is a Phase 4 study of Postpartum Hemorrhage and Twin; Complicating Pregnancy that has completed, run by Columbia University. The registered enrollment target is 66 participants, below the 199-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05772156, a Phase 4 study of Postpartum Hemorrhage and Twin; Complicating Pregnancy, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
Obstetrical hemorrhage (excessive bleeding related to pregnancy) is a leading cause of maternal morbidity (disease or symptom of disease) and mortality (death) worldwide with a significantly higher frequency and severity following cesarean delivery. Twin gestations (twin pregnancy) are at particularly higher risk for postpartum hemorrhage, yet the management of obstetrical bleeding following twin delivery remains identical to singleton delivery. The purpose of this study is to understand the effect of prophylactic methylergonovine on blood loss in scheduled twin pregnancy cesarean deliveries. Participants will be randomized (like tossing a coin) to Methylergonovine (investigational drug) or water with salt (saline) (placebo). Methylergonovine or saline will be given as an injection immediately after delivery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Methylergonovine
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2024-03-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05772156
The ClinicalTrials.gov registry entry for NCT05772156 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 11 other Postpartum Hemorrhage trials with a reported enrollment target (67% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Postpartum Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05772156 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05772156 about?
NCT05772156 is a clinical study titled "Prophylactic Methylergonovine for Twin Cesarean". Obstetrical hemorrhage (excessive bleeding related to pregnancy) is a leading cause of maternal morbidity (disease or symptom of disease) and mortality (death) worldwide with a significantly higher frequency and severity following cesarean delivery. Twin gestations (twin pregnancy) are at particular...
What is the current status of trial NCT05772156?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2023-03-07. Estimated completion is 2024-03-11.
What conditions does trial NCT05772156 study?
This clinical trial studies the following conditions: Postpartum Hemorrhage, Twin; Complicating Pregnancy.
What interventions are being tested in trial NCT05772156?
The interventions under investigation include: Placebo (DRUG), Methylergonovine (DRUG).
Who is sponsoring clinical trial NCT05772156?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05772156 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postpartum Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Effect of Intravenous Ketorolac on Opioid Use, EBL and Complications Following Cesarean Delivery
COMPLETED · Phase 4
-
Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study
COMPLETED · Phase 4
-
Safety and Effectiveness of the KOKO Device to Treat Primary Abnormal Postpartum Uterine Bleeding or Hemorrhage
RECRUITING · NA
-
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
RECRUITING · Phase 3
-
Postpartum Oxytocin Administration in the Era of Delayed Cord Clamping
COMPLETED · NA
-
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.